Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker

American Journal of Hypertension

Volumn 28, Issue 1, 2015, Pages 15-21

  Furuhashi, Masato ^a   Moniwa, Norihito ^b   Mita, Tomohiro ^a   Fuseya, Takahiro ^a   Ishimura, Shutaro ^a   Ohno, Kohei ^a   Shibata, Satoru ^a   Tanaka, Marenao ^a   Watanabe, Yuki ^a   Akasaka, Hiroshi ^a,c   Ohnishi, Hirofumi ^a   Yoshida, Hideaki ^a   Takizawa, Hideki ^b   Saitoh, Shigeyuki ^a,c   Ura, Nobuyuki ^d   Shimamoto, Kazuaki ^c   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TEINE KEIJINKAI HOSPITAL   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d Sapporo Nishimaruyama Hospital   (Japan)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme 2; Blood pressure; Hypertension; Olmesartan, urine, urinary protein

Indexed keywords

AMLODIPINE; ANGIOTENSIN CONVERTING ENZYME 2; CANDESARTAN; GLUCOSE; HEMOGLOBIN A1C; LOSARTAN; NIFEDIPINE; OLMESARTAN; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SYSTOLIC BLOOD PRESSURE; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECTS; ENZYMOLOGY; JAPAN; KIDNEY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME; UPREGULATION; URINE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; JAPAN; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDYL-DIPEPTIDASE A; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84922355681     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu086     Document Type: Article

References (42)

1. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1-9.
2. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417:822-828.
3. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002; 23:177-183.
4. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275:33238-33243.
5. Ingelfinger JR. Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 2009; 18:79-84.
6. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004; 43:1120-1125.
7. Li N, Zimpelmann J, Cheng K, Wilkins JA, Burns KD. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. Am J Physiol Renal Physiol 2005; 288:F353-F362.
8. Shaltout HA, Westwood BM, Averill DB, Ferrario CM, Figueroa JP, Diz DI, Rose JC, Chappell MC. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2- dependent processing of angiotensin II. Am J Physiol Renal Physiol 2007; 292:F82-F91.
9. Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, Crackower MA, Backx PH, Penninger JM, Scholey JW. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006; 168:1808-1820.
10. Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC, Backx PH, Penninger JM, Herzenberg AM, Scholey JW. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 2007; 171:438-451.
11. Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM, Penninger JM, Batlle D. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 2010; 55:90-98.
12. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 2010; 59:529-538.
13. Verma A, Shan Z, Lei B, Yuan L, Liu X, Nakagawa T, Grant MB, Lewin AS, Hauswirth WW, Raizada MK, Li Q. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther 2012; 20:28-36.
14. Liu CX, Hu Q, Wang Y, Zhang W, Ma ZY, Feng JB, Wang R, Wang XP, Dong B, Gao F, Zhang MX, Zhang Y. Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol Med 2011; 17:59-69.
15. Nadarajah R, Milagres R, Dilauro M, Gutsol A, Xiao F, Zimpelmann J, Kennedy C, Wysocki J, Batlle D, Burns KD. Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 2012; 82:292-303.
16. Wang G, Lai FM, Lai KB, Chow KM, Kwan CH, Li KT, Szeto CC. Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia 2008; 51:1062-1067.
17. Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem 2005; 280:39353-39362.
18. Wysocki J, Garcia-Halpin L, Ye M, Maier C, Sowers K, Burns KD, Batlle D. Regulation of urinary ACE2 in diabetic mice. Am J Physiol Renal Physiol 2013; 305:F600-F611.
19. Mizuiri S, Aoki T, Hemmi H, Arita M, Sakai K, Aikawa A. Urinary angiotensin-converting enzyme 2 in patients with CKD. Nephrology 2011; 16:567-572.
20. Xiao F, Hiremath S, Knoll G, Zimpelmann J, Srivaratharajah K, Jadhav D, Fergusson D, Kennedy CR, Burns KD. Increased urinary angiotensin- converting enzyme 2 in renal transplant patients with diabetes. PLoS One 2012; 7:e37649.
21. Park SE, Kim WJ, Park SW, Park JW, Lee N, Park CY, Youn BS. High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria. Eur J Endocrinol 2013; 168:203-210.
22. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:982-992.
23. Kawano Y, Tsuchihashi T, Matsuura H, Ando K, Fujita T, Ueshima H; Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension. Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (2) assessment of salt intake in the management of hypertension. Hypertens Res 2007; 30:887-893.
24. Kurtz TW, Pravenec M. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system. Am J Hypertens 2008; 21:852-859.
25. Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D. ACE and ACE2 activity in diabetic mice. Diabetes 2006; 55:2132-2139.
26. Alghamri MS, Weir NM, Anstadt MP, Elased KM, Gurley SB, Morris M. Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice. J Cardiovasc Pharmacol Ther 2013; 18:138-151.
27. Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007; 72:614-623.
28. Wysocki J, Batlle D. Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity? Nephrol Dial Transplant 2013; 28:2200-2202.
29. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41:392-397.
30. Ferrario CM, Jessup J, Gallagher PE, Averill DB, Brosnihan KB, Ann Tallant E, Smith RD, Chappell MC. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 2005; 68:2189-2196.
31. Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 2006; 291:H2166-H2172.
32. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43:970-976.
33. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006; 29:865-874.
34. Iwai M, Nakaoka H, Senba I, Kanno H, Moritani T, Horiuchi M. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling. Hypertension 2012; 60:137-144.
35. Inaba S, Iwai M, Furuno M, Kanno H, Senba I, Okayama H, Mogi M, Higaki J, Horiuchi M. Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. J Hypertens 2011; 29:2236-2245.
36. Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensinaldosterone system in hypertensive patients. Hypertens Res 2001; 24:641-646.
37. Gavras I, Gavras H. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr Med Res Opin 1999; 15:15-24.
38. Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7:1041-1044.
39. Bauer IH, Reams GP, Wu Z, Lau-Sieckman A. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypertens 1995; 9:237-243.
40. Varagic J, Ahmad S, VonCannon JL, Moniwa N, Brosnihan KB, Wysocki J, Batlle D, Ferrario CM. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats. Am J Hypertens 2013; 26:583-590.
41. Miura S, Karnik SS, Saku K. Angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2011; 12:1-7.
42. Ono T, Sanai T, Miyahara Y, Noda R. Olmesartan is more effective than other angiotensin receptor antagonists in reducing proteinuria in patients with chronic kidney disease other than diabetic nephropathy. Curr Ther Res Clin Exp 2013; 74:62-67.